. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: Crit Rev Oncol Hematol. 2012 Oct 23;86(3):232–250. doi: 10.1016/j.critrevonc.2012.09.014

Table 1.

Target Molecule	Mechanism	Drug (reference)

EGFR	Inhibits activating by growth signals	Cetuximab (Erbitux)	http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted
EGFR	Prevents sending growth signals	Panitumumab (Vectibix)
VEGF	Prevents it from interacting with receptors on endothelial cells	Bevacizumab (Avastin)

Macrophages	*	Vit D₃	[1]